Skip Navigation

Cardiovascular Research 2006 69(4):781-783; doi:10.1016/j.cardiores.2006.01.007
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Maio, M.
Right arrow Articles by Fonsatti, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maio, M.
Right arrow Articles by Fonsatti, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Is it the primetime for endoglin (CD105) in the clinical setting?

Michele Maioa,b,*, Maresa Altomontea and Ester Fonsattia

aDivision of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, 53100 Siena, Italy
bCancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy

* Corresponding author. Division of Medical Oncology and Immunotherapy, University Hospital of Siena, Strada delle Scotte 14, 53100 Siena, Italy. Tel.: +39 0577 586335; fax: +39 0577 586303. Email address: mmaio@cro.it

Received 30 December 2005; accepted 9 January 2006

The first 10% of the full text of this article appears below.

See article by Jerkic et al. [12] (pages 845–854) in this issue.

Initial studies carried out at the beginning of the past century identified increased vascularity as a common feature associated with tumor growth; based on these morphological observations, it was then demonstrated that local tumor growth and distant metastasis of neoplastic cells are strictly dependent on adequate blood supply. The latter was subsequently shown to be provided by blood vessels neoformed from pre-existing ones whose growth is directly promoted by neoplastic cells through the local release of angiogenic factors. Altogether, these observations provided a strong scientific . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
E. Fonsatti, H. J.M. Nicolay, M. Altomonte, A. Covre, and M. Maio
Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours
Cardiovasc Res, October 30, 2009; (2009) cvp332v2.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. S. Svatek, J. A. Karam, C. G. Roehrborn, P. I. Karakiewicz, K. M. Slawin, and S. F. Shariat
Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy
Clin. Cancer Res., June 1, 2008; 14(11): 3362 - 3366.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. A. Dallas, S. Samuel, L. Xia, F. Fan, M. J. Gray, S. J. Lim, and L. M. Ellis
Endoglin (CD105): A Marker of Tumor Vasculature and Potential Target for Therapy
Clin. Cancer Res., April 1, 2008; 14(7): 1931 - 1937.
[Abstract] [Full Text] [PDF]